John D. Carroll is a biotech analyst and writer with decades of prize-winning experience in journalism. A co-founder of Endpoints News, he has covered biopharma for the past 15 years. Aside from ...

If all goes according to plan, insitro could finally start testing its first drug in clinical trials in 2026, eight years after Daphne Koller founded the AI-powered biotech. To get ...

The planned exit of longstanding Pfizer CSO Mikael Dolsten comes at a pivotal moment for the huge drugmaker. The Covid-19 vaccine aura has fully worn off, it’s made a spate ...

After creating antibody makers Apogee and Spyre, Paragon Therapeutics is back with another inflammatory and immune disease biotech, and the startup is immediately going to the public markets ...

Below are notable updates from the American Academy of Dermatology’s annual meeting over the weekend: Sanofi amends trial protocol Sanofi has big plans for amlitelimab, the monoclonal antibody ...

Eli Lilly’s CDK4/6 inhibitor Verzenio barely missed the overall survival endpoint in a Phase III clinical trial for advanced breast cancer. In the MONARCH 3 study, 493 women received either ...

As Eli Lilly launches its newly approved weight loss med Zepbound to much fanfare, Novo Nordisk is tossing a next-gen candidate in the ring. The Danish pharma company is launching ...

When actor Bellamy Young was growing up, her father suffered from a brain disorder called hepatic encephalopathy (HE) caused by cirrhosis of the liver. She knows the stigma and isolation ...

The FDA recently added a new warning and precaution to the label of Horizon's blockbuster monoclonal antibody Tepezza (teprotumumab-trbw), which is used as a treatment for thyroid eye disease, to ...

Just a few days after pricing a $150 million public offering, Iovance has now closed with 15% more raised, thanks to underwriters pitching in. Iovance priced ...

Sandoz, Boehringer Ingelheim, Organon/Samsung and others are now taking their shot at AbbVie's megablockbuster Humira, with launches of their biosimilars on Saturday, and myriad approaches to take ...

Novacyt made a cash offer for molecular diagnostics and screening solutions company Yourgene Health as it adjusts from a major drop in revenue due to declining demand for Covid-19 diagnostics ...